Navinci announces Omni is a multiplex in situ proximity ligation assay with a fluorescent readout, enabling the simultaneous detection of up to 9 protein–protein interactions, post-translational modifications, or single protein targets with high specificity and sensitivity.
Navinci is proud to announce the launch of the Naveni® Plex Omni Service, giving researchers access to cutting edge multiplex isPLA technology.
Navinci is proud to introduce Naveni® Plex, the first multiplex in situ proximity ligation assay, allowing for the simultaneous detection of three separate targets or protein-protein interactions.
Leica Biosystems and Navinci collaborate to automate in situ proximity ligation assays, now with fluorescent readout.
Introducing Naveni® CD8/MHC-I in situ assay kit, revealing immune response intricacies. Revolutionize cancer treatment with nuanced insights, advancing precision medicine.
Would you like to perform a proximity ligation assay using your own primary antibodies? Our NaveniLink conjugation kit allows you to do just that.
This cutting-edge kit is meticulously fine-tuned for in situ cell analysis and delivers enhanced signal strength, a shorter protocol including a separate protocol for 96-well plates.
Illuminate PD1/PD-L1 interactions – new product out! 23-06-12 Uppsala Navinci expands its portfolio to unravel PD1 signaling, introducing the fluorescent assay, Naveni™ PD1/PD-L1 Atto 647N. With Naveni™ PD1/PD-L1 Atto 647N, you can now achieve a comprehensive visualization of the tumor microenvironment through co-staining. Illuminate PD1/PD-L1 interactions like never before and gain a deeper understanding of…
An eye-opening solution for tissue samples – launch of NaveniFlex™ Tissue Looking for protein-protein interactions or post-translational modifications in tissues? We’ve got you covered. The advanced Naveni™ proximity ligation technology we developed for NaveniFlex™ Tissue kits are tailor-made to overcome common background challenges in tissue samples. The kits are optimized for tissue samples to deliver…
Quantify phospho-VEGFR2 in situ Navinci is expanding the Naveni PTM product line! Quantify phosphorylated VEGFR2 with outstanding signal-to-noise ratio. Receptor tyrosine kinases (RTKs) are involved in cellular processes and altered phosphorylation states may lead to disturbed signaling pathways, tumor progression, and cancer. Specific tools for quantifying phosphorylation of RTKs in situ have been requested for…
LAUNCH NEWS Navinci is taking the next step to meet the needs of the pathology field. NaveniBright is a new product line with chromogenic readout. The in situ kits are based on our Naveni Proximity Ligation Technology and significantly enhance the chromogenic signal, providing you with stronger and more accurate staining. The assay gives you detailed…